BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 15503294)

  • 1. High-dose ifosfamide in relapsed pediatric osteosarcoma: therapeutic effects and renal toxicity.
    Berrak SG; Pearson M; Berberoğlu S; Ilhan IE; Jaffe N
    Pediatr Blood Cancer; 2005 Mar; 44(3):215-9. PubMed ID: 15503294
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ifosfamide tolerance in osteosarcoma patients previously treated with cis-diamminedichloroplatinum-II: renal, hematologic, and neurologic observations.
    Canpolat C; Pearson P; Robertson R; Jaffe N
    Med Pediatr Oncol; 1996 Jan; 26(1):36-47. PubMed ID: 7494510
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neoadjuvant chemotherapy with high-dose Ifosfamide, high-dose methotrexate, cisplatin, and doxorubicin for patients with localized osteosarcoma of the extremity: a joint study by the Italian and Scandinavian Sarcoma Groups.
    Ferrari S; Smeland S; Mercuri M; Bertoni F; Longhi A; Ruggieri P; Alvegard TA; Picci P; Capanna R; Bernini G; Müller C; Tienghi A; Wiebe T; Comandone A; Böhling T; Del Prever AB; Brosjö O; Bacci G; Saeter G;
    J Clin Oncol; 2005 Dec; 23(34):8845-52. PubMed ID: 16246977
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Can cure in patients with osteosarcoma be achieved exclusively with chemotherapy and abrogation of surgery?
    Jaffe N; Carrasco H; Raymond K; Ayala A; Eftekhari F
    Cancer; 2002 Nov; 95(10):2202-10. PubMed ID: 12412175
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase I/II study of doxorubicin, ifosfamide, etoposide and interval methotrexate in patients with poor prognosis osteosarcoma.
    McTiernan A; Meyer T; Michelagnoli MP; Lewis I; Whelan JS
    Pediatr Blood Cancer; 2006 Mar; 46(3):345-50. PubMed ID: 16206197
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ifosfamide/etoposide alternating with high-dose methotrexate: evaluation of a chemotherapy regimen for poor-risk osteosarcoma.
    Michelagnoli MP; Lewis IJ; Gattamaneni HR; Bailey CC; Lashford LS
    Br J Cancer; 1999 Mar; 79(7-8):1174-8. PubMed ID: 10098754
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High-dose methotrexate pharmacokinetics and outcome of children and young adults with osteosarcoma.
    Crews KR; Liu T; Rodriguez-Galindo C; Tan M; Meyer WH; Panetta JC; Link MP; Daw NC
    Cancer; 2004 Apr; 100(8):1724-33. PubMed ID: 15073863
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Pilot study of relapsed osteosarcoma and brain tumor with ifosfamide, carboplatin and etoposide (ICE therapy)].
    Hirota T; Takeuchi M; Iwata A; Kitagawa S; Sato T; Konno K; Sawada K; Kobayashi S; Hamaguchi N; Agata H; Katano N; Fujimoto T
    Gan To Kagaku Ryoho; 1998 Feb; 25(3):385-90. PubMed ID: 9492832
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Renal toxicity of ifosfamide in pilot regimens of the intergroup rhabdomyosarcoma study for patients with gross residual tumor.
    Raney B; Ensign LG; Foreman J; Khan F; Newton W; Ortega J; Ragab A; Wharam M; Wiener E; Maurer H
    Am J Pediatr Hematol Oncol; 1994 Nov; 16(4):286-95. PubMed ID: 7978043
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pattern of disease recurrence and prognostic factors in patients with osteosarcoma treated with contemporary chemotherapy.
    Hawkins DS; Arndt CA
    Cancer; 2003 Dec; 98(11):2447-56. PubMed ID: 14635080
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oral etoposide for recurrent/progressive sarcomas of childhood.
    Kebudi R; Görgün O; Ayan I
    Pediatr Blood Cancer; 2004 Apr; 42(4):320-4. PubMed ID: 14966827
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase II study of cisplatin, ifosfamide and epirubicin combination chemotherapy in adults with nonmetastatic and extremity osteosarcomas.
    Basaran M; Bavbek ES; Saglam S; Eralp L; Sakar B; Atalar AC; Bilgic B; Ozger H; Onat H
    Oncology; 2007; 72(3-4):255-60. PubMed ID: 18185020
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neoadjuvant chemotherapy for radioinduced osteosarcoma of the extremity: The Rizzoli experience in 20 cases.
    Bacci G; Longhi A; Forni C; Fabbri N; Briccoli A; Barbieri E; Mercuri M; Balladelli A; Ferrari S; Picci P
    Int J Radiat Oncol Biol Phys; 2007 Feb; 67(2):505-11. PubMed ID: 17118571
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival--a report from the Children's Oncology Group.
    Meyers PA; Schwartz CL; Krailo MD; Healey JH; Bernstein ML; Betcher D; Ferguson WS; Gebhardt MC; Goorin AM; Harris M; Kleinerman E; Link MP; Nadel H; Nieder M; Siegal GP; Weiner MA; Wells RJ; Womer RB; Grier HE;
    J Clin Oncol; 2008 Feb; 26(4):633-8. PubMed ID: 18235123
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The effects of high-dose ifosfamide in the treatment of bone and soft tissue sarcomas].
    Ishii T; Tatezaki S; Satoh T; Yonemoto T; Umeda T; Kitoh M
    Gan To Kagaku Ryoho; 1997 Nov; 24(14):2123-30. PubMed ID: 9388523
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preoperative hyperfractionated chemoradiation for locally recurrent rectal cancer in patients previously irradiated to the pelvis: A multicentric phase II study.
    Valentini V; Morganti AG; Gambacorta MA; Mohiuddin M; Doglietto GB; Coco C; De Paoli A; Rossi C; Di Russo A; Valvo F; Bolzicco G; Dalla Palma M;
    Int J Radiat Oncol Biol Phys; 2006 Mar; 64(4):1129-39. PubMed ID: 16414206
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intraarterial Cisplatin and intravenous adriamycin in nonmetastatic osteosarcoma of the extremities: a single institution experience in Taiwan.
    Chiu TJ; Wang JW; Chen YJ; Tang Y; Huang CH
    Chang Gung Med J; 2009; 32(1):72-80. PubMed ID: 19292942
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate.
    Meyers PA; Schwartz CL; Krailo M; Kleinerman ES; Betcher D; Bernstein ML; Conrad E; Ferguson W; Gebhardt M; Goorin AM; Harris MB; Healey J; Huvos A; Link M; Montebello J; Nadel H; Nieder M; Sato J; Siegal G; Weiner M; Wells R; Wold L; Womer R; Grier H
    J Clin Oncol; 2005 Mar; 23(9):2004-11. PubMed ID: 15774791
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Toxic effects of ifosfamide in the treatment of bone and soft tissue sarcomas].
    Ishii T; Umeda T; Kitoh M; Tatezaki S; Satoh T
    Gan To Kagaku Ryoho; 1993 Mar; 20(4):509-14. PubMed ID: 8452388
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Results of the EICESS-92 Study: two randomized trials of Ewing's sarcoma treatment--cyclophosphamide compared with ifosfamide in standard-risk patients and assessment of benefit of etoposide added to standard treatment in high-risk patients.
    Paulussen M; Craft AW; Lewis I; Hackshaw A; Douglas C; Dunst J; Schuck A; Winkelmann W; Köhler G; Poremba C; Zoubek A; Ladenstein R; van den Berg H; Hunold A; Cassoni A; Spooner D; Grimer R; Whelan J; McTiernan A; Jürgens H;
    J Clin Oncol; 2008 Sep; 26(27):4385-93. PubMed ID: 18802150
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.